IDH-mutant glioma
Response and survival, trial by trial.
Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.
1 arm has a reported figure in this set.
Vorasidenib 1
Vorasidenib 40 mg daily
40 mg · ITT
grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery only (n = 168 vs 163)
Comparator: placebo
PFS hazard ratio vs placebo (BIRC): 0.39 HR, primary analysis
time to next intervention hazard ratio: 0.26 HR, primary analysis
INDIGO · NCT04164901
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.